Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Schizophrenia
Interventions
DRUG

ketamine

"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.~No drug administration for patients with schizophrenia"

Trial Locations (1)

06516

VHA CT, West Haven

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Yale University

OTHER